Business Description
Genomma Lab Internacional SAB de CV
ISIN : MX01LA010006
Share Class Description:
MEX:LABB: Class BTotal Employee Number:
1,665Compare
Compare
Traded in other countries / regions
LABB.MexicoGNMLF.USAGEKA.Germany IPO Date
2008-06-18Description
Genomma Lab Internacional SAB de CV is a specialty and generic drug manufacturer. The company's stated goal is to improve and preserve the health and well-being of people through innovative, safe, and effective products. Genomma operates a wide variety of brands to serve different consumer needs, including pregnancy, pain medication, and deodorant. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.35 | |||||
Equity-to-Asset | 0.47 | |||||
Debt-to-Equity | 0.69 | |||||
Debt-to-EBITDA | 2.3 | |||||
Interest Coverage | 4.91 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 2.79 | |||||
Beneish M-Score | -2.49 | |||||
WACC vs ROIC | ||||||
Growth Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 1.9 | |||||
3-Year EBITDA Growth Rate | 7.1 | |||||
3-Year EPS without NRI Growth Rate | 3.6 | |||||
3-Year FCF Growth Rate | 0.4 | |||||
3-Year Book Growth Rate | 2.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 14.82 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 6.14 |
Momentum Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 63.54 | |||||
9-Day RSI | 53.28 | |||||
14-Day RSI | 47.7 | |||||
3-1 Month Momentum % | -10.72 | |||||
6-1 Month Momentum % | -13.77 | |||||
12-1 Month Momentum % | -23.88 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.79 | |||||
Quick Ratio | 1.53 | |||||
Cash Ratio | 0.37 | |||||
Days Inventory | 116.48 | |||||
Days Sales Outstanding | 106.96 | |||||
Days Payable | 101.24 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Dividend Yield % | 5.32 | |||||
Dividend Payout Ratio | 0.43 | |||||
3-Year Dividend Growth Rate | -11.3 | |||||
Forward Dividend Yield % | 5.32 | |||||
5-Year Yield-on-Cost % | 5.46 | |||||
3-Year Average Share Buyback Ratio | -0.5 | |||||
Shareholder Yield % | -1.06 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 62.99 | |||||
Operating Margin % | 21.4 | |||||
Net Margin % | 9.25 | |||||
EBITDA Margin % | 20.22 | |||||
FCF Margin % | 11.2 | |||||
OCF Margin % | 11.41 | |||||
ROE % | 14.27 | |||||
ROA % | 6.66 | |||||
ROIC % | 13.04 | |||||
3-Year ROIIC % | 52.18 | |||||
ROC (Joel Greenblatt) % | 35.34 | |||||
ROCE % | 18.86 | |||||
Years of Profitability over Past 10-Year | 9 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 9.16 | |||||
Forward PE Ratio | 7.29 | |||||
PE Ratio without NRI | 8.05 | |||||
Shiller PE Ratio | 13.18 | |||||
Price-to-Owner-Earnings | 8.79 | |||||
PEG Ratio | 1.02 | |||||
PS Ratio | 0.84 | |||||
PB Ratio | 1.25 | |||||
Price-to-Tangible-Book | 2.41 | |||||
Price-to-Free-Cash-Flow | 7.57 | |||||
Price-to-Operating-Cash-Flow | 7.43 | |||||
EV-to-EBIT | 6.15 | |||||
EV-to-Forward-EBIT | 8.69 | |||||
EV-to-EBITDA | 5.51 | |||||
EV-to-Forward-EBITDA | 4.81 | |||||
EV-to-Revenue | 1.11 | |||||
EV-to-Forward-Revenue | 1.11 | |||||
EV-to-FCF | 9.9 | |||||
Price-to-GF-Value | 0.85 | |||||
Price-to-Projected-FCF | 0.51 | |||||
Price-to-Median-PS-Value | 0.61 | |||||
Price-to-Peter-Lynch-Fair-Value | 0.84 | |||||
Price-to-Graham-Number | 0.93 | |||||
| Price-to-Net-Current-Asset-Value | 25.49 | |||||
Earnings Yield (Greenblatt) % | 16.23 | |||||
FCF Yield % | 13.19 | |||||
Forward Rate of Return (Yacktman) % | 21.83 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Genomma Lab Internacional SAB de CV Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | 17,325.455 | ||
| EPS (TTM) (MXN) | 1.644 | ||
| Beta | 0.0511 | ||
| 3-Year Sharpe Ratio | -0.09 | ||
| 3-Year Sortino Ratio | -0.14 | ||
| Volatility % | 23.87 | ||
| 14-Day RSI | 47.7 | ||
| 14-Day ATR (MXN) | 0.488916 | ||
| 20-Day SMA (MXN) | 14.9325 | ||
| 12-1 Month Momentum % | -23.88 | ||
| 52-Week Range (MXN) | 14.24 - 23.6 | ||
| Shares Outstanding (Mil) | 977.75 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Genomma Lab Internacional SAB de CV Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Genomma Lab Internacional SAB de CV Stock Events
| Event | Date | Price (MXN) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-10-23 11:00 | In 120 days | ||
| Third quarter earnings results for 2026 | 2026-10-22 | In 118 days | ||
| Second quarter earnings conference call for 2026 | 2026-07-24 11:00 | In 29 days | ||
| Second quarter earnings results for 2026 | 2026-07-23 | In 27 days | ||
| General meeting for 2026 | 2026-07-03 | In 7 days | ||
| MXN 0.200000 Cash Dividend | 2026-06-26 | 14.42 (+1.19%) | ||
| Annual report for 2025 | 2026-04-30 | 16.30 (-0.12%) | ||
| First quarter earnings conference call for 2026 | 2026-04-23 11:00 | 18.70 (-3.46%) | ||
| First quarter earnings results for 2026 | 2026-04-22 | 18.70 (-3.46%) | ||
| MXN 0.200000 Cash Dividend | 2026-03-30 | 17.28 (-1.37%) |
Show
Entries
Genomma Lab Internacional SAB de CV Frequently Asked Questions
What is Genomma Lab Internacional SAB de CV(MEX:LABB)'s stock price today?
The current price of MEX:LABB is MXN15.04. The 52 week high of MEX:LABB is MXN23.60 and 52 week low is MXN14.24.
When is next earnings date of Genomma Lab Internacional SAB de CV(MEX:LABB)?
The next earnings date of Genomma Lab Internacional SAB de CV(MEX:LABB) is 2026-07-23 Est..
Does Genomma Lab Internacional SAB de CV(MEX:LABB) pay dividends? If so, how much?
The Dividend Yield %  of Genomma Lab Internacional SAB de CV(MEX:LABB) is 5.32% (As of Today), Highest Dividend Payout Ratio of Genomma Lab Internacional SAB de CV(MEX:LABB) was 0.75. The lowest was 0.33. And the median was 0.45. The  Forward Dividend Yield % of Genomma Lab Internacional SAB de CV(MEX:LABB) is 5.32%. For more information regarding to dividend, please check our Dividend Page.
Press Release
Articles on Genomma Lab Internacional SAB de CV
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers